The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. - Wikidata - wikimedia - TriplyDB

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.

http://www.wikidata.org/entity/Q33226589

about

Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging Selective activation of TNFR1 and NF-κB inhibition by a novel biyouyanagin analogue promotes apoptosis in acute leukemia cells.Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor κB kinase.NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.NF-kappa B as a target for cancer therapy.Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells.ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines Activation of AMPK enhances neutrophil chemotaxis and bacterial killing.IκB kinase b Mediating the Downregulation of p53 and p21 by Lipopolysaccharide in Human Papillomavirus 16+ Cervical Cancer Cells.Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NFκB survival-signaling pathway IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.The NFκB pathway: a therapeutic target in glioblastoma.NF-κB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death.Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia.Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.NF-κB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells.Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids.Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.NF-κB in Hematological Malignancies.Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species

P2860

Q26849792-72FF93EC-7D57-4182-9A6F-5FAF3D06DBF0 Q28115315-46D2A97D-832C-4CAD-8F4C-FD73384AC359 Q33490384-23994894-215A-4CCD-975D-1629C64B52DD Q33944952-357DAF37-15F9-4109-AA1D-EF0D02BF5F2D Q34032208-3AFB5E1E-031C-45E3-9377-E1F70D133F1A Q35995213-9E136CC2-234E-4C66-B249-0041815D68BD Q36204370-298CFAB3-3854-457A-8623-6C487C80B4C9 Q36311738-F189CEEE-915B-4BC4-B58E-EAF932032F62 Q36414254-54DC641A-D0EB-4E42-B520-2108A2ED92A7 Q36485168-7428FAC4-EEF5-4156-81A7-3B005BA0B842 Q36491838-7B42322A-E8A7-49BB-ADA8-3DC5CEFB629C Q36709532-B8A8C485-A4AD-42A5-B699-BA8E5E896739 Q37023880-C83DA23E-9A21-47A3-A0A8-574C6E32FA80 Q37109225-9487148D-E079-464E-8873-5F9EBDB046DD Q37109468-F2D4FD6C-BC4B-4A74-8E1B-C5BA3ABBE205 Q37162871-C44EF004-0586-4268-8FC3-C3442BC35365 Q37446058-625F932F-236D-4E69-B26D-9439490C011D Q37447488-54A86E38-1827-4CD3-98DF-65974686D67F Q37488862-E5E97B7B-ADC7-4F55-94DA-72190E52AEA7 Q37697852-B49066CF-D70A-4115-AF05-0D4D8DCD8417 Q37928304-1800FF87-500B-4669-AE3A-4694971B906F Q38281185-ECA070D2-7149-4A96-B12A-7C431F73CADB Q38710822-2AB27029-9CA0-4F50-977E-E9CC596D13EC Q38882194-874F2F32-70E8-487C-92D9-CBEB781FA113 Q38937733-AF040FEF-FF11-40F1-B826-4BF6A93D95D1 Q39908969-4A32F8CA-6182-45FA-90CE-020D374BA4C7 Q41547633-1FCE084F-7E80-4DE9-A9DD-5A6819FA0D15 Q41842515-3741F57C-EE13-411B-B310-6F267987AB13 Q41979732-5E08C01F-8B0E-47F1-86D2-CEE6D39F4206 Q45071199-B3928165-230C-4D5F-9976-4EAC7E1805F1 Q45290867-37E0724A-ED79-42F9-BE20-70EE1E474F7B Q51747038-58126B5A-9C3C-4C7B-A593-9DE56EF7A02C Q54147337-B2E7144F-0888-48BD-9381-6393FC2DC075 Q58799959-BFE6209E-F1B1-4CDA-ADD1-057FA7A3CBE7

P2860

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.

http://www.wikidata.org/entity/Q33226589

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

The NF-kappaB pathway blockade ...... overcome imatinib resistance.

@ast

The NF-kappaB pathway blockade ...... overcome imatinib resistance.

@en

type

label

The NF-kappaB pathway blockade ...... overcome imatinib resistance.

@ast

The NF-kappaB pathway blockade ...... overcome imatinib resistance.

@en

prefLabel

The NF-kappaB pathway blockade ...... overcome imatinib resistance.

@ast

The NF-kappaB pathway blockade ...... overcome imatinib resistance.

@en

P1433

Q33226589-09319206-6204-45AC-8001-D60D0048F4C6

P1476

Q33226589-811CDA8C-D020-4827-B906-3EC2E3A0D3A2

P2093

Q33226589-244C0719-B5BE-4B44-A2A2-B2C2B99F497B

Q33226589-251761C8-8E15-415E-AAA0-FF07E7C2E654

Q33226589-298E6A70-CF2B-416D-9E47-A7D88FC0321E

Q33226589-44779966-A2C7-4CF8-A20E-0524B120FBF8

Q33226589-5DC42E8E-69A1-43A6-8CC7-21493C784842

Q33226589-612960C7-6F6D-47FB-945F-BE9CF74EBFA8

Q33226589-7D7CDD29-084B-48C1-8C63-3E59B32608E0

Q33226589-8E778917-490F-4FCF-B535-BF6120B08656

Q33226589-A6A16CAB-3C0F-4E79-AFEF-554FE26245AD

Q33226589-B1A6867A-0CFD-4CF0-921C-B3578EAB8EBD

P2860

Q33226589-03F807BE-9437-442C-BE4B-983EE28F55E6

Q33226589-0F2B2A78-FA68-4B2E-B97C-6A8BEAAF9AF8

Q33226589-1913CB70-083C-48C8-B119-63B087C9F26C

Q33226589-1EAFB583-4F57-4FED-8790-B4C3BBD655E8

Q33226589-255BBB9A-47BB-4556-8A5C-4003A4D074BC

Q33226589-3AE9A909-C805-4C89-8083-F35F513E48C3

Q33226589-4A121F61-03B2-4B61-BEB1-B674778D0854

Q33226589-515CD6BD-DC65-4B3E-851E-980710A02D40

Q33226589-53F17337-D7E7-461F-8303-F1BB46636044

Q33226589-694E695D-2DC6-4CF0-8166-AC40D5601050

P2888

Q33226589-323CE0E5-BB14-47CA-B8C8-264FC51E298A

P304

Q33226589-CAFF196B-64E4-4139-95BB-76C1EDE4995F

P31

Q33226589-C3F58047-6FB4-4409-8B19-FBBC4D3CED4B

P356

Q33226589-5E0DF403-A62A-499D-A520-354363E7802C

P433

Q33226589-58EE1A14-8D3C-4B98-9135-44014140A952

P478

Q33226589-CF227180-5FDD-48A2-B2F1-4B33EBAA679F

P577

Q33226589-70323871-F6C2-44EE-9EC4-9497A2163658

P5875

Q33226589-CCC1F817-10D7-4255-816B-A3DDA858634D

P6179

Q33226589-8BE53B3D-DE41-4772-9616-DE593E432E7E

P698

Q33226589-BDAD9C44-7AF6-4F4E-A783-B8ADCFB28ED6

P921

Q33226589-E2E38395-DFDA-4208-95BE-EEE16E0FE4B4

P356

P1433

P1476

The NF-kappaB pathway blockade ...... overcome imatinib resistance.

@en

P2093

Arruga F

http://www.w3.org/2001/XMLSchema#string

Baccarani M

http://www.w3.org/2001/XMLSchema#string

Bracco E

http://www.w3.org/2001/XMLSchema#string

Carturan S

http://www.w3.org/2001/XMLSchema#string

Cilloni D

http://www.w3.org/2001/XMLSchema#string

Defilippi I

http://www.w3.org/2001/XMLSchema#string

Giugliano E

http://www.w3.org/2001/XMLSchema#string

Martinelli G

http://www.w3.org/2001/XMLSchema#string

Messa E

http://www.w3.org/2001/XMLSchema#string

Messa F

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

c-Abl: activation and nuclear targets

Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation

Nuclear transcription factor-kappaB as a target for cancer drug development

Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl

The Abl family kinases: Mechanisms of regulation and signaling

Missing pieces in the NF-kappaB puzzle

Activators and target genes of Rel/NF-kappaB transcription factors

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

NF-kappaB at the crossroads of life and death

P2888

P304

61-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2403998

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7498135

http://www.w3.org/2001/XMLSchema#string

P6179

1012733961

http://www.w3.org/2001/XMLSchema#string

P698

16270044

http://www.w3.org/2001/XMLSchema#string

P921